

January 28, 2022

To The Manager, Listing Department <b>National Stock Exchange of India</b> Plot no. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: <b>BLISSGVS</b>	To The General Manager, Listing Department <b>BSE Limited</b> Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: <b>506197</b>
---	--

Dear Sir/Madam,

**Subject: Intimation of Incorporation of Step-Down Subsidiary**

**Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

With reference to the captioned subject, we would like to inform you that "Bliss GVS International PTE Ltd" Singapore, a wholly owned subsidiary of Bliss GVS Pharma Limited ("the Company"), has incorporated a wholly owned subsidiary namely, Asterisk Lifesciences Democratic Republic of Congo ("DRC").

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated 9<sup>th</sup> September, 2015 are enclosed as "Annexure - A".

This is for your information and record.

Thanking you.

Yours faithfully,  
For Bliss GVS Pharma Limited

Vipul Thakkar  
Chief Financial Officer



**Regd. Office :** 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL. : (+91) (22) 42160000/ 28505387 • FAX. : (+91) (22) 28563930,

Email : info@blissgvs.com • Website : www.blissgvs.com • CIN - L24230MH1984PLC034771

**Factory :**

Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax : (+91) (02525) 255257. • Email : factory@blissgvs.com

**Annexure - A**

Details regarding incorporation of a step-down subsidiary in Democratic Republic of Congo

Sr. No.	Particulars	Details
1	Name of the target entity, details in brief such as size, turnover etc.	Asterisk Lifesciences DRC Turnover: Not applicable since this is newly incorporated Company
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter / promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	"Bliss GVS International PTE Ltd" Singapore, a subsidiary of the Company, has incorporated a wholly owned subsidiary namely, "Asterisk Lifesciences DRC". Incorporation of Asterisk Lifesciences DRC is a related party for the Company. Further, none of the promoter/promoter group companies have any interests in the newly incorporated entity.
3	Industry to which the entity being acquired belongs	Pharmaceutical formulations, APIs., Cosmetics, Confectionery, food items, healthcare services, machinery, process equipment, diagnostic and medical equipments.
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The Company's purpose is: <ul style="list-style-type: none"> <li>• Marketing, distribution &amp; sale of pharmaceutical formulations at affordable prices for the local market;</li> <li>• Sale of pharmaceutical and para pharmaceutical products, articles, equipment, supplies and materials of all kinds;</li> <li>• Consignment and wholesale distribution of all imported pharmaceutical and para pharmaceutical articles, products and goods.</li> </ul>

		<ul style="list-style-type: none"> <li>• Any operation of importation, purchase and storage of drugs and other health products with a view to their distribution directly to the various pharmacies and authorized health structures.</li> <li>• Importation, Selling and distribution of pharmaceutical formulations, APIs, cosmetics, confectionary, food item, machineries, process equipments, healthcare services, diagnostics, medical equipments, pharmacy, warehousing, manufacturing of pharmaceutical formulations, packaging &amp; repackaging of pharmaceutical, cosmetic and allied products.</li> </ul>
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6	Indicative time period for completion of the acquisition;	Not applicable
7	Nature of consideration - whether cash consideration or share swap and details of the same;	It is newly formed subsidiary with Share Capital of USD 1000.
8	Cost of acquisition or the price at which the shares are acquired;	USD 1,000 as Share Capital Contribution
9	Percentage of shareholding / control acquired and / or number of shares acquired;	Bliss GVS International PTE Ltd" Singapore, a subsidiary of the Company, owns 100% in the new entity viz." Asterisk Lifesciences DRC"
10	Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The entity is newly incorporated. Date of incorporation: Jan 15, 2022 Last 3 years turnover: Not applicable Country of incorporation: Democratic Republic of Congo